Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a review of medical history and current health status.

Participants must discontinue all medications used to treat Tourette Syndrome for at least 14 days before randomization. Other psychotropic drugs are allowed if stable for at least 30 days prior to randomization.

Participants are randomly assigned to receive either the study medication, gemlapodect, or a placebo. This process is double-blind, meaning neither the participant nor the study team knows which treatment is being administered.

Participants take the assigned medication orally in the form of hard capsules. The dosage and frequency are determined by the study protocol and are consistent throughout the 12-week study period.

Throughout the study, regular assessments are conducted to monitor health and response to the medication. These include evaluations of tic severity, using the YGTSS-R scale, and other health indicators such as body weight, blood glucose, and lipids.

Additional assessments include laboratory tests, ECGs, and vital signs monitoring. Participants are also evaluated for any adverse effects.

At the end of the 12-week period, a final evaluation is conducted. This includes a comprehensive review of all collected data to assess the efficacy and safety of the treatment.

The primary focus is on changes in tic severity scores from the start of the study to the end, comparing gemlapodect to the placebo.